Harrow, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Harrow, Inc. (HROW) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -2.27% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-02
- Harrow, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -2.27%.
- Harrow, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -1.87%.
- Harrow, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -0.43%.
- Harrow, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was -7.53%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -2.27% 10-K · filed 2026-03-02 | |
| 2024-12-31 | -1.87% 10-K · filed 2026-03-02 | |
| 2023-12-31 | -0.43% 10-K · filed 2026-03-02 | 2.97% 10-K · filed 2024-03-19 |
| 2021-12-31 | -7.53% 10-K · filed 2022-03-10 | |
| 2020-12-31 | -0.38% 10-K · filed 2022-03-10 | |
| 2019-12-31 | -358.67% 10-K · filed 2021-03-08 | |
| 2018-12-31 | 0.13% 10-K · filed 2020-03-13 | |
| 2017-12-31 | 3.04% 10-K · filed 2019-03-12 | |
| 2016-12-31 | -0.18% 10-K · filed 2018-03-08 | |
| 2015-12-31 | -0.71% 10-K · filed 2017-03-21 | |
| 2014-12-31 | -0.21% 10-K · filed 2016-03-23 | |
| 2013-12-31 | -0.08% 10-K · filed 2015-03-12 | 0.08% 10-K · filed 2014-03-28 |
| 2012-12-31 | -0.04% 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |